Intracerebral Gene Therapy for Sanfilippo Type A Syndrome

Access Programs

Disease Information

Descriptive Information
Brief Title † Intracerebral Gene Therapy for Sanfilippo Type A Syndrome
Official Title † An Open-label, Single Arm, Monocentric, Phase I/II Clinical Study of Intracerebral Administration of Adeno-associated Viral Vector Serotype 10 Carrying the Human SGSH and SUMF1 cDNAs for the Treatment of Sanfilippo Type A Syndrome.
Brief Summary The clinical trial P1-SAF-301 is an open-label, single arm, monocentric, phase I/II clinical study evaluating the tolerance and the safety of intracerebral administration of adeno-associated viral vector serotype 10 carrying the human SGSH and SUMF1 cDNAs for the treatment of Sanfilippo type A syndrome The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session. The primary objective is to assess the tolerance and the safety associated to the proposed treatment through a one-year follow up. The secondary objective is to collect data to define exploratory tests that could become evaluation criteria for further clinical phase III efficacy studies. Four patients will be included in the clinical trial and will be followed during one year. The enrollment and the follow-up of the patients will take place at Bicêtre Hospital. The Neurosurgery will be performed at Necker-Enfants Malades Hospital. Safety will be evaluating on clinical, radiological and biological parameters.
Detailed Description
Study Phase Phase 1/Phase 2
Study Type † Interventional
Study Design † Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Outcome Measure † Tolerance and safety
Secondary Outcome Measure † To collect data to define exploratory tests that could become evaluation criteria for further clinical phase III efficacy studies
Condition † Mucopolysaccharidosis Type III A Sanfilippo Disease Type A
Intervention † GeneticSAF-301
Study Arms / Comparison Groups SAF-301
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Genetic
Estimated Enrollment † 4
Start Date † August 2011
Completion Date May 2013
Primary Completion Date May 2013
Eligibility Criteria † Inclusion Criteria: - Age: 18 (eighteen) months to end of 6 (six) years - Onset of clinical manifestations related to MPSIIIA during the first 5 years of life - SGSH activity in peripheral blood cell and / or cultured fibroblast extracts of less than 10% of controls. - Patient affiliated to the French social security or assimilated regimens - Family understanding the procedure and the informed consent - Signed informed consent - Vital laboratory parameters within normal range Exclusion Criteria: - Presence of brain atrophy on inclusion MRI judged on a cortico-dural distance of more than 1cm - No independent walking (Ability to walk without help) - Any condition that would contraindicate permanently anaesthesia - Any other permanent medical condition not related to MPSIIIA - Any vaccination 1 month before investigational drug administration - Intake of aspirin within one month - Any medication aiming at modifying the natural course of MPSIIIA given during the 6 months before vector injection - Any condition that would contraindicate treatment with Prograf®, Modigraf®, Cellcept® and Solupred®
Gender Both
Ages 18 Months - 6 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries † France
Administrative Information
NCT ID † NCT01474343
Organization ID P1-SAF-301
Secondary IDs ††
Responsible Party Sponsor
Study Sponsor † LYSOGENE
Collaborators ††
Investigators † : ,
Information Provided By
Verification Date May 2014
First Received Date † November 10, 2011
Last Updated Date May 5, 2014
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Harish Ravi
by Abidemi Uruejoma
Free Newsletter